UPDATED Apr 29, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$737.20 | 0.8% | 81.7% | US$660.7b | US$813.32 | PE126.7x | E27.2% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$489.03 | -0.4% | -1.3% | US$455.8b | US$567.36 | PE29.3x | E19.2% | 1.5% | Healthcare | ||
JNJ | US$146.82 | -1.5% | -10.3% | US$352.2b | US$173.60 | PE18.5x | E5.1% | 3.4% | Pharmaceuticals & Biotech | ||
MRK | US$130.12 | 2.5% | 11.8% | US$332.3b | US$140.93 | PE142.9x | E26.1% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$161.52 | -3.8% | 5.1% | US$282.6b | US$182.65 | PE48.1x | E23.4% | 3.8% | Pharmaceuticals & Biotech | ||
AZN | UK£120.24 | 6.9% | 2.4% | UK£186.4b | UK£131.45 | PE37x | E16.6% | 2.1% | Pharmaceuticals & Biotech | ||
TMO | US$576.89 | 5.2% | 5.2% | US$219.0b | US$620.33 | PE36.5x | E11.9% | 0.3% | Pharmaceuticals & Biotech | ||
ABT | US$107.27 | 0.2% | -3.5% | US$186.6b | US$126.33 | PE33.2x | E11.3% | 2.1% | Healthcare | ||
DHR | US$246.82 | 4.5% | 2.1% | US$182.6b | US$269.86 | PE44.9x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
AMGN | US$276.38 | 1.6% | 15.7% | US$144.8b | US$303.26 | PE22.1x | E9.0% | 3.3% | Pharmaceuticals & Biotech | ||
PFE | US$25.64 | -2.4% | -34.6% | US$143.8b | US$31.62 | PE68x | E22.3% | 6.6% | Pharmaceuticals & Biotech | ||
ISRG | US$374.14 | 1.4% | 23.5% | US$133.1b | US$420.59 | PE66.8x | E11.6% | n/a | Healthcare | ||
SYK | US$338.87 | 3.4% | 13.0% | US$127.6b | US$365.69 | PE40.7x | E12.7% | 0.9% | Healthcare | ||
ELV | US$533.98 | 0.3% | 13.1% | US$124.9b | US$599.48 | PE19.9x | E12.5% | 1.2% | Healthcare | ||
BSX | US$72.50 | 6.6% | 37.3% | US$107.6b | US$80.66 | PE60.4x | E18.2% | n/a | Healthcare | ||
MDT | US$80.86 | 0.4% | -10.8% | US$105.9b | US$94.75 | PE25.6x | E10.3% | 3.4% | Healthcare | ||
VRTX | US$396.20 | -0.9% | 14.8% | US$102.7b | US$459.72 | PE28.3x | E11.5% | n/a | Pharmaceuticals & Biotech | ||
CI | US$356.44 | 0.9% | 39.8% | US$100.5b | US$381.44 | PE19.6x | E9.6% | 1.6% | Healthcare | ||
REGN | US$892.48 | -0.9% | 10.6% | US$95.3b | US$1,038.08 | PE24.4x | E11.2% | n/a | Pharmaceuticals & Biotech | ||
BMY | US$44.64 | -9.2% | -34.7% | US$90.9b | US$53.76 | PS2x | E43.0% | 5.4% | Pharmaceuticals & Biotech | ||
CSL | AU$276.76 | -0.8% | -8.3% | AU$132.9b | AU$306.74 | PE35.4x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
GSK | UK£16.70 | 1.9% | 15.9% | UK£68.2b | UK£20.06 | PE13.8x | E9.3% | 3.5% | Pharmaceuticals & Biotech | ||
CVS | US$67.45 | -3.1% | -8.7% | US$84.7b | US$87.96 | PE10.2x | E6.8% | 3.9% | Healthcare | ||
GILD | US$65.94 | -1.5% | -19.0% | US$81.6b | US$84.10 | PE169.5x | E35.8% | 4.7% | Pharmaceuticals & Biotech |